Windlas Biotech Limited has informed the Exchange regarding Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 regarding grant of Stock Options/ Units under WBL Employee Stock Option Scheme 2023 ( ESOS 2023 ) and Windlas Plan 2025 ( Plan )
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech Limited has announced the grant of 37,000 stock options/units to eligible employees under two schemes. The Nomination and Remuneration Committee approved 15,750 options under the WBL Employee Stock Option Scheme 2023 (ESOS 2023) and 21,250 units under the Windlas Plan 2025. Each option/unit entitles the holder to one equity share of Rs. 5 face value. For ESOS 2023, the exercise price may include up to 25% discount from market price, while Windlas Plan 2025 units are granted at face value. Vesting periods range from 1-4 years with exercise windows of up to 4 years from vesting.
This represents minor equity dilution of 37,000 shares. The options are spread over multiple years of vesting and exercise, so immediate dilution impact is limited. This is a routine employee retention initiative that aligns staff interests with shareholder value.